SCHEMBL2056415

SCHEMBL2056415

CC(C)c1ccc2c(c1)C(O)C(=O)N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
POLB P06746 2/20 0.42
TP53 P04637 6/20 0.39
MDM2 Q00987 4/20 0.39
RNASEH1 O60930 1/20 0.39
HPGD P15428 3/20 0.38
GFER P55789 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PGR P06401 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
TYR P14679 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MDM4 O15151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20251044 0.81 PGR (0.50) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL17807750 0.80 MAOB (0.47) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL29955187 0.78 PIM1 (0.39) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL8210790 0.77 MEN1 (0.39) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL14438188 0.74 NQO2 (0.50) MAPTKMT2APOLBTP53ALDH1A1
SCHEMBL2054640 0.73 MEN1 (0.42) MAPTMEN1KMT2ATDP1TP53
SCHEMBL2056355 0.73 SMN1; SMN2 (0.42) MAPTKDM4ETDP1TP53MDM2
SCHEMBL17260218 0.70 GSK3B (0.49) MAPTKDM4ETP53MDM2ALDH1A1
SCHEMBL87439 0.69 IDO1 (0.50) MAPTKDM4ETDP1POLBHPGD
SCHEMBL17707913 0.69 DYRK1A (0.50) MAPTKDM4ETDP1TP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases GENFIT (FR) 2021-07-06 US disclosed
US-8163749-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-24 US disclosed
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL -MEYERS SQUIBB COMPANY 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases RORA, RORC, RORB MAPT 3199/4885KDM4E 1701/4885MEN1 4303/4885
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS TFPI, F11, F12 MAPT 726/4885KDM4E 1947/4885MEN1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.